incretin and glp-1 The mechanisms of dual receptor agonists. Glucagon-like GLP-1 Agonists: Increasing Effective Insulin

Long term administration of agonists could potentially lead to unanticipated consequences in these organs

Gastrointestinal events have appeared most frequently in trials (nausea, vomiting, diarrhea)

Glucagon-like peptide-1 (GLP-1) receptor agonistsmedications originally developed for type 2 diabetesare emerging as a potential treatment option for PCOS due to their effects on insulin sensitivity, weight management, and hormonal regulation

Over the course of two years, Emma saw significant improvements in her insulin sensitivity, lipid profile, and overall metabolic health, reducing her risk of developing related comorbidities